Predicting Alzheimer's disease based on survival data and longitudinally measured performance on cognitive and functional scales

Yan Wu,Xinnan Zhang,Yao He,Jing Cui,Xiaoyan Ge,Hongjuan Han,Yanhong Luo,Long Liu,Xuxia Wang,Hongmei Yu,the Alzheimer's Disease Neuroimaging Initiative
DOI: https://doi.org/10.1016/j.psychres.2020.113201
IF: 11.3
2020-09-01
Psychiatry Research
Abstract:<p>This study assessed how well longitudinally taken cognitive and functional scales from people with mild cognitive impairment (MCI) predict conversion to Alzheimer's disease (AD). Participants were individuals with baseline MCI from the Alzheimer's Disease Neuroimaging Initiative. Scales included the Alzheimer Disease Assessment Scale-Cognitive (ADAS-Cog) 11 and 13, the Mini Mental State Examination (MMSE), and the Functional Assessment Questionnaire (FAQ). A joint modelling approach compared performance on the four scales for dynamic prediction of risk for AD. The goodness of fit measures included log likelihood, AIC (Akaike Information Criterion) and BIC (Bayesian Information Criterion). The area under the curve (AUC) of the receiver operating characteristic assessed predictive accuracy. The parameter α in the ADAS-Cog11, ADAS-Cog13, MMSE, and FAQ joint models was statistically significant. Joint MMSE and FAQ models had better goodness of fit. FAQ had the best predictive accuracy. Cognitive and functional impairment assessment scales are strong screening predictors when repeated measures are available. They could be useful for predicting risk for AD in primary healthcare.</p>
psychiatry
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to evaluate the ability of longitudinal cognitive and functional scales to predict the conversion to Alzheimer's disease (AD) in patients with mild cognitive impairment (MCI). Specifically, the researchers used data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and analyzed the performance of four scales (ADAS - Cog 11, ADAS - Cog 13, MMSE, and FAQ) in dynamically predicting AD risk through a joint modeling approach. The goal of the study was to determine whether these scales can be used as effective screening tools, especially in the primary healthcare setting, for monitoring cognitive decline and predicting the development of AD. ### Main research questions: 1. **Evaluation of predictive ability**: Evaluate the effectiveness of longitudinally collected cognitive and functional scales (ADAS - Cog 11, ADAS - Cog 13, MMSE, and FAQ) in predicting the conversion of MCI patients to AD. 2. **Model comparison**: Compare the goodness - of - fit and predictive accuracy of different scales in the joint model. 3. **Analysis of influencing factors**: Explore the influence of factors such as age, gender, education level, marital status, and ApoE ε4 gene status on cognitive and functional decline. ### Research methods: - **Data source**: Use data from the ADNI database, including participants with a baseline of MCI. - **Scale selection**: Select four scales: ADAS - Cog 11, ADAS - Cog 13, MMSE, and FAQ. - **Statistical analysis**: Adopt a joint modeling method, including a longitudinal sub - model and a survival sub - model. The longitudinal sub - model is used to describe the changes in cognition and function over time, and the survival sub - model is used to predict the risk of AD conversion. ### Research results: - **Predictive ability**: The FAQ scale showed the best predictive accuracy in predicting AD conversion, followed by ADAS - Cog and MMSE. - **Influencing factors**: Age, marital status, education level, gender, and ApoE ε4 gene status are related to cognitive decline in MCI patients. - **Model fitting**: The joint model based on MMSE and FAQ had the best fitting effect. ### Conclusion: This study shows that longitudinal assessment using cognitive and functional scales can effectively predict the risk of MCI patients converting to AD, especially the FAQ scale which performs best in terms of predictive accuracy. These scales have practical value in the primary healthcare setting and can help doctors and family caregivers to intervene in a timely manner and delay the progress of the disease.